Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

The main difference between NNVC and IPIX is that a nanoviricide has never advanced to any clinical study, not even a phase 1. Unspoken in 16 years of preclinical testing is that animals have repeatedly shown inflammation following any application and even topical applications pass through the space between cells and enter the circulatory system.

Brilacidin, on the other hand, has gone through phase 1 and 2 trials both before and after purchase by IPIX/CTIX. Safety issues have been successfully resolved. The question left is whether or not Brilacidin can be an effective antiviral treatment. That question will be answered shortly.